Furthermore, the addition of Bmab to oxaliplatin-based regimens (i.e., CapeOX and FOLFOX) as adjuvant chemotherapy for colorectal cancer has been reported to have negative results and is not recommended [18], suggesting that VEGF inhibitors are not expected to have additional effects as NAC for colorectal cancer. Here, VEGFA is linked to colorectal cancer.